Two top NEXT Winners…
THE FUTURE IS BRIGHT FOR ICM RESEARCH!
Part of ESICM’s vision for the future has hinged on promoting our young specialists through our ESICM NEXT Initiative. This year, we would like to shine a spotlight on two of our NEXT members who have been selected to receive some of our most prestigious research awards.
2017 Featured Award Winners:
NEXT START-UP GRANT
Dept of Surgical Sciences
Mechanisms of inflammation in spontaneous breathing during mechanical ventilation. A PET-CT experimental study in a mild ARDS model.
Spontaneous breathing (SB) is discouraged in acute respiratory distress syndrome (ARDS) due to unpredictable inhomogeneous regional transpulmonary pressures, assumed to cause lung injury and inflammation. We hypothesise that adequate support of SB (“optimal SB”) would instead stabilise the lungs and downregulate the inflammatory reaction and could, thus, be beneficial in ARDS.
We plan to investigate whether the regional distribution of the inflammatory reaction is reduced in optimal SB compared with non-optimal SB or
controlled mechanical ventilation, using Positron Emitting Tomography and Computed Tomography (PET/CT) imaging technique.
Project starting date: 02/10/2017
Project duration: 24 months
ESICM YOUNG INVESTIGATOR AWARD
Department of Medicine I / Intensive Care Unit 13i2
Medical University of Vienna
Characteristics and outcomes of cancer patients with Acute Respiratory Distress Syndrome potentially fulfilling inclusion criteria for veno-venous extracorporeal membrane oxygenation: a multicentre prospective descriptive analysis “The YELENNA Study”.
The planned research constitutes a prospective multinational observational ingestigation on the characteristics and outcomes of cancer patients with ARDS, with a focus on patients with severe ARDS and specifically those fulfilling “virtual” inclusion criteria for venovenous ECMO.
The study will be conducted to systematically describe the characteristics, outcomes, and associated risk factors of adult cancer patients with ARDS. Characteristics of the underlying malignancy, as well as ARDS specific information will be portrayed. The subgroup of patients with severe ARDS will be analysed in more depth. In these patients, the presence of inclusion criteria for use of veno-venous ECMO will be screened. Therefore, our investigation will identify the proportion and incidence of patients possibly eligible for a future interventional trial.
Project starting date: 01/10/2017
Project duration: 18 months
Both of these award-winning researchers will be honoured today in the final session of LIVES 2017.
Watch it LIVE in Vienna or online HERE…
HOT TOPICS SESSION ~ Awards + Clinical Trials Presentations
17.09.2017, 14:10 – 17:20, room Vienna
Reach out to NEXT members on social media: